Home › Research › Risk factors
Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?
Robel K Gebre, Jonathan Graff‐Radford, Vijay K. Ramanan, Sheelakumari Raghavan, Ekaterina I. Hofrenning, Scott A. Przybelski, Aivi T. Nguyen, Timothy G. Lesnick et al.. Brain Communications, 2024-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
For amyloid positive individuals Aβ42/Aβ40, glial fibrillary acidic protein and p-tau181 were the top predictors of cognitive decline while Aβ42/Aβ40 was prominent for amyloid negative participants across all age groups. Socio-demographics explained a large portion of the variance in the amyloid negative individuals while the plasma biomarkers predominantly explained the variance in amyloid positive individuals (21% to 37% from the younger to the older age group). Plasma biomarkers performed similarly to MRI and cardiovascular measures when predicting cognitive outcomes and combining them with either measure resulted in better performance. Top predictors were heterogeneous between cross-sectional and longitudinal cognition models, across age groups, and amyloid status. Multimodal approaches will enhance the usefulness of plasma biomarkers through careful considerations of a study population’s socio-demographics, brain and cardiovascular health.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 1,185 participants. This study tested whether combining Alzheimer's plasma biomarkers with MRI, cardiovascular, genetic, and lifestyle measures improves prediction of cognition. It concerns prediction, not treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gebre, R. K., Graff‐Radford, J., Ramanan, V. K., Raghavan, S., Hofrenning, E. I., Przybelski, S. A., et al. (2024). Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction? Brain Communications. https://doi.org/10.1093/braincomms/fcae300
Vancouver
Gebre RK, Graff‐Radford J, Ramanan VK, Raghavan S, Hofrenning EI, Przybelski SA, et al. Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction? Brain Communications. 2024. doi:10.1093/braincomms/fcae300. PMID: 39291164.
BibTeX
@article{gebre2024-39291164,
author = {Gebre, Robel K and Graff‐Radford, Jonathan and Ramanan, Vijay K. and Raghavan, Sheelakumari and Hofrenning, Ekaterina I. and Przybelski, Scott A. and Nguyen, Aivi T. and Lesnick, Timothy G. and others},
title = {{Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?}},
journal = {Brain Communications},
year = {2024},
doi = {10.1093/braincomms/fcae300},
pmid = {39291164},
url = {https://doi.org/10.1093/braincomms/fcae300}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- For amyloid positive individuals Aβ42/Aβ40, glial fibrillary acidic protein and p-tau181 were the top predictors of cognitive decline while Aβ42/Aβ40 was prominent for amyloid negative participants across all age groups.
- Socio-demographics explained a large portion of the variance in the amyloid negative individuals while the plasma biomarkers predominantly explained the variance in amyloid positive individuals (21% to 37% from the younger to the older age group).
- Plasma biomarkers performed similarly to MRI and cardiovascular measures when predicting cognitive outcomes and combining them with either measure resulted in better performance.
- Top predictors were heterogeneous between cross-sectional and longitudinal cognition models, across age groups, and amyloid status.
- Multimodal approaches will enhance the usefulness of plasma biomarkers through careful considerations of a study population’s socio-demographics, brain and cardiovascular health.
Why it matters
This study tested whether combining Alzheimer's plasma biomarkers with MRI, cardiovascular, genetic, and lifestyle measures improves prediction of cognition. It concerns prediction, not treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Study designcross-sectional
- Participants1,185
- Evidence strengthModerate
How this study scored 53/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain Communications) |
| Journal's citation record | 0 / 4 | Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,185 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 1.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Prashanthi Vemuri: h-index 106 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39291164) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1093/braincomms/fcae300
- PubMed: 39291164
- Original source →
- Free full text: Brain Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Risk factors from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.